Browse the evidence

At 5-6 months, the mean weight reduction was 7.9%, with 56% of participants achieving more than 5% weight loss.

Phentermine/topiramate ER can be effective for weight loss in obese patients.

At 12 months, patients who persisted in treatment experienced an average weight loss of 9.6%, with 65% surpassing a 5% weight loss.

Long-term adherence to treatment can lead to significant weight loss.

Efsubaglutide Alfa produced a mean weight reduction of 7.16% versus 0.86% with placebo.

Efsubaglutide Alfa may be an effective treatment option for weight loss in individuals with obesity or overweight.

82.5% of Efsubaglutide-treated participants achieved ≥5% weight loss.

A significant proportion of individuals treated with Efsubaglutide Alfa can expect to achieve clinically meaningful weight loss.

Cagrisema produced significantly greater percentage weight loss than semaglutide with a mean difference of -7.47% (95% CI: -10.58, -4.36; p < 0.001).

Cagrisema may be a more effective option for weight loss in obese patients compared to semaglutide.

Cagrilintide monotherapy weight loss was comparable to semaglutide.

Cagrilintide may be a viable alternative to semaglutide for weight management in obese patients.

Cagrisema is safe and has a comparable side effect profile to semaglutide.

Cagrisema can be considered a safe option for weight management in obese patients.

The mean change in body weight was -10.5% with semaglutide and -2.0% with placebo.

Semaglutide may lead to significant weight loss in patients with MASH.

Higher weight loss was associated with a lower hazard of discontinuation for both patients with and without type 2 diabetes.

Encouraging weight loss may improve adherence to GLP-1 RA therapy.

Once-weekly cagrilintide-semaglutide (at a dose of 2.4 mg each) resulted in a significantly lower body weight than placebo in adults with obesity and type 2 diabetes.

Practitioners can consider cagrilintide-semaglutide as an effective treatment for weight management in this population.

More patients in the cagrilintide-semaglutide group than in the placebo group had a weight reduction of 5% or more.

Cagrilintide-semaglutide may be particularly effective for achieving clinically significant weight loss.

Metabolic bariatric surgery (MBS) was associated with greater total weight loss (mean 28.3%) compared to GLP-1 receptor agonists (mean 10.3%) in patients with class II and III obesity.

MBS may be a more effective option for significant weight loss in patients with higher obesity classes.

Plant-based dietary patterns rich in minimally processed foods, vegetables, and fruits reduce CVD risk.

Health professionals should recommend plant-based diets rich in whole foods to reduce CVD risk.

The Mediterranean, Dietary Approaches to Stop Hypertension, and vegetarian diets reduce CVD risk.

Health professionals should promote these specific dietary patterns to lower CVD risk.

Tirzepatide administration for 72 weeks elicited significant weight reduction ranging from 5% to 20.9% across different trials in a dose-dependent manner.

Tirzepatide may be an effective option for weight management in patients with obesity and T2DM.

Semaglutide led to a weight reduction of 9.21 kg in the study population.

Semaglutide may assist in significant weight loss for patients in this demographic.

The working group recommends dietary consultations, increased physical activity, resistance training, and potential use of oral nutritional supplements and medications for managing sarcopenic obesity.

Practitioners should consider these recommendations for effective management of sarcopenic obesity.

Glucagon coagonists like survodutide and mazdutide have demonstrated significant weight loss and improved glycemic control.

These agents may be effective options for patients needing weight loss and glycemic control.

Calorie restriction, structured exercise, pharmacotherapy, and metabolic surgeries have shown beneficial effects in reducing VAT.

Implementing these strategies can effectively reduce visceral fat.

After 3 months, average weight loss was 4.11 kg or 4.57%.

Practitioners can expect significant weight loss in patients using semaglutide in a real-world setting.

Individuals lost fat mass (2.67 kg) and trunk fat mass (1.10 kg).

Practitioners can expect reductions in fat mass among patients using semaglutide.

GLP-1s reduce body weight by 5% to 18% in trials.

Clinicians can expect significant weight loss in patients using GLP-1s.

HU6 treatment for 19 weeks significantly decreased body weight by -2.86 kg compared to placebo (P = .003).

HU6 may be an effective treatment option for weight loss in patients with obesity-related HFpEF.

HU6 treatment significantly decreased total fat mass by -2.96 kg compared to placebo (P < .001).

HU6 may help reduce fat mass in patients with obesity-related HFpEF.